Karen McAdam
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Karen McAdam has a total of 75 co-authors. Here are the top co-authors by number of shared publications:
- Carlos Caldas
Department of Clinical Biochemistry and Institute of Metabolic Science, School of Clinical Medicine, University of Cambridge, Cambridge, UK
15 shared publications - Elena Provenzano
Addenbrookes Hospital and NIHR Cambridge Biomedical Research Centre, Cambridge, UK
15 shared publications - Jean E. Abraham
Department of Oncology, University of Cambridge, Hills Road, Cambridge CB2 0QQ, United Kingdom
14 shared publications - Abigail Shea
Department of Oncology, Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge, United Kingdom
13 shared publications - Agnese Giovannetti
Clinical Genomics Laboratory, Fondazione IRCCS Casa Sollievo della Sofferenza, S. Giovanni Rotondo (FG), Italy
13 shared publications - Ai Nagano
Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK
13 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Legends from Modeling Drug Responses and Evolutionary Dynamics Using Patient-Derived Xenografts Reveals Precision Medicine Strategies for Triple-Negative Breast Cancer
Supplementary Figures 1-20 and Supplementary Tables 1-10 Legends
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Legends from Modeling Drug Responses and Evolutionary Dynamics Using Patient-Derived Xenografts Reveals Precision Medicine Strategies for Triple-Negative Breast Cancer
Supplementary Figures 1-20 and Supplementary Tables 1-10 Legends
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure 6 from Modeling Drug Responses and Evolutionary Dynamics Using Patient-Derived Xenografts Reveals Precision Medicine Strategies for Triple-Negative Breast Cancer
In vivo treatment causes permanent changes to a tumor’s drug response profile. A, Experimental framework of in vivo and ex vivo drug response profiling. B, High-throughput drug screening data of dissociated PDTX cells. AUC plots display the response of each tumor to drugs tested ex vivo. Color indicates the in vivo treatment to which each tumor was previously exposed. C, Dose–response curves of models 1040 (top) and 1141 (bottom) to olaparib and BMN-673. Plots compare the untreated PDTX tumors (black) to those previously treated in vivo with CT (red). D, Experimental framework to test alternative sequencing strategies of CT and olaparib in vivo using model 1040. Untreated PDTX tumors and those previously treated with CT or olaparib were each passaged into three cohorts of mice. These mice were left untreated or subsequently exposed to CT or olaparib. E, Estimated mean tumor growth for each experimental group. Panels display previous treatment groups (first-line treatment), and lines within each panel display the cohort of second-line treatment. F, Estimated log-daily growth rate of PDTX tumors, as predicted by the linear mixed models. Column panels display previous treatment groups (first-line treatment), and lines within each panel display the cohort of second-line treatment. G, Predicted tumor (log) volume at treatment end of each cohort treated sequentially with no treatment, CT, or olaparib based on the linear mixed models. Panels display previous treatment groups (first-line treatment), and boxes within each panel display the cohort of second-line treatment.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 6 from Modeling Drug Responses and Evolutionary Dynamics Using Patient-Derived Xenografts Reveals Precision Medicine Strategies for Triple-Negative Breast Cancer
In vivo treatment causes permanent changes to a tumor’s drug response profile. A, Experimental framework of in vivo and ex vivo drug response profiling. B, High-throughput drug screening data of dissociated PDTX cells. AUC plots display the response of each tumor to drugs tested ex vivo. Color indicates the in vivo treatment to which each tumor was previously exposed. C, Dose–response curves of models 1040 (top) and 1141 (bottom) to olaparib and BMN-673. Plots compare the untreated PDTX tumors (black) to those previously treated in vivo with CT (red). D, Experimental framework to test alternative sequencing strategies of CT and olaparib in vivo using model 1040. Untreated PDTX tumors and those previously treated with CT or olaparib were each passaged into three cohorts of mice. These mice were left untreated or subsequently exposed to CT or olaparib. E, Estimated mean tumor growth for each experimental group. Panels display previous treatment groups (first-line treatment), and lines within each panel display the cohort of second-line treatment. F, Estimated log-daily growth rate of PDTX tumors, as predicted by the linear mixed models. Column panels display previous treatment groups (first-line treatment), and lines within each panel display the cohort of second-line treatment. G, Predicted tumor (log) volume at treatment end of each cohort treated sequentially with no treatment, CT, or olaparib based on the linear mixed models. Panels display previous treatment groups (first-line treatment), and boxes within each panel display the cohort of second-line treatment.
- Open Access
- 1 February 2025
- Published by American Association for Cancer Research (AACR)
Figure 2 from Modeling Drug Responses and Evolutionary Dynamics Using Patient-Derived Xenografts Reveals Precision Medicine Strategies for Triple-Negative Breast Cancer
A coclinical trial framework reveals concordant patient–PDTX drug responses. A, Experimental framework (consisting of two trial designs) and associated analytical approach, with modeling metrics used to assess drug response. B and C, TV growth curves displaying linear mixed model fits of trial designs 1 (B) and 2 (C) over treatment duration. Treatment arm for each PDTX model corresponds to the clinical treatment of the matched patient. D and E, Analytical metrics derived from mathematical modeling (as in A). Change in growth rate (top) and estimated difference in the AUC (bottom) for trial design 1 (D) and growth rate under treatment (top) and predicted volume at treatment end (bottom) for trial design 2 (E). F, Box plots displaying growth rate under treatment (top) and predicted volume at treatment end (bottom) for trial design 2 between pCR and non-pCR models. Statistical significance is calculated using the Wilcoxon test.
- 1 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 2 from Modeling Drug Responses and Evolutionary Dynamics Using Patient-Derived Xenografts Reveals Precision Medicine Strategies for Triple-Negative Breast Cancer
A coclinical trial framework reveals concordant patient–PDTX drug responses. A, Experimental framework (consisting of two trial designs) and associated analytical approach, with modeling metrics used to assess drug response. B and C, TV growth curves displaying linear mixed model fits of trial designs 1 (B) and 2 (C) over treatment duration. Treatment arm for each PDTX model corresponds to the clinical treatment of the matched patient. D and E, Analytical metrics derived from mathematical modeling (as in A). Change in growth rate (top) and estimated difference in the AUC (bottom) for trial design 1 (D) and growth rate under treatment (top) and predicted volume at treatment end (bottom) for trial design 2 (E). F, Box plots displaying growth rate under treatment (top) and predicted volume at treatment end (bottom) for trial design 2 between pCR and non-pCR models. Statistical significance is calculated using the Wilcoxon test.
- Open Access
- 1 February 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Tables 1-5 from Modeling Drug Responses and Evolutionary Dynamics Using Patient-Derived Xenografts Reveals Precision Medicine Strategies for Triple-Negative Breast Cancer
Supplementary Tables 1-5 from Modeling Drug Responses and Evolutionary Dynamics Using Patient-Derived Xenografts Reveals Precision Medicine Strategies for Triple-Negative Breast Cancer
- 1 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables 1-5 from Modeling Drug Responses and Evolutionary Dynamics Using Patient-Derived Xenografts Reveals Precision Medicine Strategies for Triple-Negative Breast Cancer
Supplementary Tables 1-5 from Modeling Drug Responses and Evolutionary Dynamics Using Patient-Derived Xenografts Reveals Precision Medicine Strategies for Triple-Negative Breast Cancer
- Open Access
- 1 February 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Legends from Modeling Drug Responses and Evolutionary Dynamics Using Patient-Derived Xenografts Reveals Precision Medicine Strategies for Triple-Negative Breast Cancer
Supplementary Figures 1-20 and Supplementary Tables 1-10 Legends
- 1 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Legends from Modeling Drug Responses and Evolutionary Dynamics Using Patient-Derived Xenografts Reveals Precision Medicine Strategies for Triple-Negative Breast Cancer
Supplementary Figures 1-20 and Supplementary Tables 1-10 Legends
- Open Access
- 1 February 2025
- Published by American Association for Cancer Research (AACR)
Figure 5 from Modeling Drug Responses and Evolutionary Dynamics Using Patient-Derived Xenografts Reveals Precision Medicine Strategies for Triple-Negative Breast Cancer
Olaparib treatment causes permanent phenotypic changes due to TF reprogramming. A, Heatmap displaying z-score (scaled by row) of the top 250 strong and variable genes. Clustering analysis performed using Euclidean distances. Columns indicate PDTX samples (labeled by mouse number). B, Top 10 significant gene sets by normalized enrichment score (NES) between untreated and post-treated samples, identified by GSEA (Hallmark gene sets). DN, down. C, IHC for phenotypic markers. D, Western blot for E-cadherin and vimentin. E, scRNA-seq data of all cells analyzed post-QC. Color indicates cell states (groups of MCs). F, Average gene expression (number of UMIs per 1,000 UMIs) of key markers across MCs. G, Percentage of cells from each condition that reside in each cell state. Immune-Act, immune activation. H, Top, epithelial and mesenchymal scores for individual MCs. Bottom, MC composition of each strata using mesenchymal minus epithelial scores to stratify MCs into 5 groups (EMT1–5). I, Top, mesenchymal and IER scores for individual MCs. Bottom, MC composition of each strata using the IER score to stratify MCs into 4 groups (IER1–4). J and K, Mean enrichment (log2 gene enrichment score) across strata for TFs of interest: EMT1–5 (J) and IER1–4 (K).
- 1 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 5 from Modeling Drug Responses and Evolutionary Dynamics Using Patient-Derived Xenografts Reveals Precision Medicine Strategies for Triple-Negative Breast Cancer
Olaparib treatment causes permanent phenotypic changes due to TF reprogramming. A, Heatmap displaying z-score (scaled by row) of the top 250 strong and variable genes. Clustering analysis performed using Euclidean distances. Columns indicate PDTX samples (labeled by mouse number). B, Top 10 significant gene sets by normalized enrichment score (NES) between untreated and post-treated samples, identified by GSEA (Hallmark gene sets). DN, down. C, IHC for phenotypic markers. D, Western blot for E-cadherin and vimentin. E, scRNA-seq data of all cells analyzed post-QC. Color indicates cell states (groups of MCs). F, Average gene expression (number of UMIs per 1,000 UMIs) of key markers across MCs. G, Percentage of cells from each condition that reside in each cell state. Immune-Act, immune activation. H, Top, epithelial and mesenchymal scores for individual MCs. Bottom, MC composition of each strata using mesenchymal minus epithelial scores to stratify MCs into 5 groups (EMT1–5). I, Top, mesenchymal and IER scores for individual MCs. Bottom, MC composition of each strata using the IER score to stratify MCs into 4 groups (IER1–4). J and K, Mean enrichment (log2 gene enrichment score) across strata for TFs of interest: EMT1–5 (J) and IER1–4 (K).
- Open Access
- 1 February 2025
- Published by American Association for Cancer Research (AACR)
Figure 1 from Modeling Drug Responses and Evolutionary Dynamics Using Patient-Derived Xenografts Reveals Precision Medicine Strategies for Triple-Negative Breast Cancer
A preclinical platform of TNBC PDTXs. A, Clinical treatment and responses of the patient cohort from which the PDTX models used in this study were derived. B, Experimental framework of the coclinical trial. C, Top, correlation plots comparing GSEA enrichment scores (Hallmark and C6 gene sets) for models 1006, 1040, 1022, and 1141. Bottom, correlation plots comparing mutation VAFs for model 1006. Correlation was calculated between passages, sister mice, and multiple regions of the same tumor using Spearman correlation.
- 1 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 1 from Modeling Drug Responses and Evolutionary Dynamics Using Patient-Derived Xenografts Reveals Precision Medicine Strategies for Triple-Negative Breast Cancer
A preclinical platform of TNBC PDTXs. A, Clinical treatment and responses of the patient cohort from which the PDTX models used in this study were derived. B, Experimental framework of the coclinical trial. C, Top, correlation plots comparing GSEA enrichment scores (Hallmark and C6 gene sets) for models 1006, 1040, 1022, and 1141. Bottom, correlation plots comparing mutation VAFs for model 1006. Correlation was calculated between passages, sister mice, and multiple regions of the same tumor using Spearman correlation.